Skip to Main Content
  • Login
  • Contact Us
  • Donate

NANETS

  • About
    • Mission
    • Board of Directors
    • Committees
    • NANETS Presidents
    • Lifetime Achievement
    • Outstanding Service
    • History
    • Diversity Statement
  • Education
    • NETCast Podcast Series
    • 2023 NET Medical Symposium
    • Regional NET Education
    • Virtual Programming Series
    • Upcoming Symposia
    • Conference Archives
    • NETMed Webinar Archives
    • About NETs
  • Research
    • Abstracts Library
    • Abstract Instructions
    • Research Grants
    • Grant Recipients
    • Grant Instructions
  • Guidelines
  • Resources
    • Grant Resources
    • NANETS Mentorship Program
    • Employment Postings
    • Clinical Trials
    • Member DirectoryMember Directory
    • NET Around the World
    • Patient Resources
    • Women in NETs
    • COVID-19 Resource Page
    • NANETS Collaboration Submission Form
  • News
    • NET eNews
    • Media
    • Endocrine-Related CancerEndocrine-Related Cancer
    • Photo Gallery
  • Membership
    • Member Login
    • Member Benefits
    • Member Categories
    • Join NOW
    • Code of Conduct
  • 2022

  • 2021

  • 2020

  • 2019

  • 2018

  • 2017

  • 2016

  • 2015

  • 2014

  • 2013

  • 2012

  • 2011

  • 2010

  • 2009

2022 Symposium Abstract Poster Quick Guide

Published in 2022

Download

[B10] Schwarz - Inhibition of Estrogen Receptor Alpha Radiosensitizes Neuroendocrine Tumors

Published in 2022 Listed under Basic Science

Download

[B11] Cortez - Patient-Derived Organoids and Their Potential for Precision Medicine in Neuroendocrine Tumors

Published in 2022 Listed under Basic Science

Download

[B12] Herring - Transcriptomic Influences of Racial Disparities in Black Patients with Pancreatic Neuroendocrine Tumors

Published in 2022 Listed under Basic Science

Download

[B13] DePietro - Optical Genome Mapping: a Novel Approach to Identifying Structural Variants in Metastatic Neuroendocrine Tumors

Published in 2022 Listed under Basic Science

Download

[B14] Amin - Pancreatic Mixed Acinar-Neuroendocrine Carcinoma: a Single Institutional Genomic Characterization Report

Published in 2022 Listed under Basic Science

Download

[B15] Scotto - Targeting the TCA Cycle with Histone Deacetylase and Nicotinamide Phosphoribosyltransferase Inhibitors Uncovers a Critical Role for YAP1 in Neuroendocrine Cells

Published in 2022 Listed under Basic Science

Download

[B16] Schultz - [212Pb]PSC-PEG2-TOC Therapy for NET Leads to Complete Responses in Mice Bearing SSTR2 Positive Tumors – Comparison to [177Lu]DOTATATE in a Preclinical Model

Published in 2022 Listed under Basic Science

Download

[B1] Rajhans - Single-Cell ATAC and Single-Nucleus RNA Sequencing Uncovers Cellular Heterogeneity Within Pancreatic Neuroendocrine Tumors

Published in 2022 Listed under Basic Science

Download

[B2] Madigan - Multiple Layers of Epigenetic Regulation Cooperate to Silence Expression of Somatostatin Receptor Type 2 in Pancreatic Neuroendocrine Tumors

Published in 2022 Listed under Basic Science

Download

[B3] Pelle - Development of a Novel Anti-SSTR Bispecific T-Cell Engager (BiTE)-like Molecule for the Treatment of Neuroendocrine Tumors

Published in 2022 Listed under Basic Science

Download

[B4] Whitt - Simultaneous Inhibition of DNA Methylation and Histone De-acetylation for Enhanced SSTR2 Expression In Vitro

Published in 2022 Listed under Basic Science

Download

[B5] Hallenbeck - Oncolytic Seneca Valley Virus (SVV-001) Overcomes Checkpoint Inhibitor Resistance and Demonstrates a Systemic Anti-tumor Response in a Syngeneic Tumor Model

Published in 2022 Listed under Basic Science

Download

[B6] Guenter - Detecting Cell Surface Expression of Calreticulin in Pancreatic Neuroendocrine Tumors Using a Novel [68Ga]-Radiolabeled Peptide

Published in 2022 Listed under Basic Science

Download

[B7] Williams - All-Trans Retinoic Acid Radiosensitizes Neuroendocrine Tumor Cells via Peptidyl-Prolyl Cis- Trans Isomerase 1 Inhibition

Published in 2022 Listed under Basic Science

Download

[B8] Kaemmer - CDK4/6-MEK Targeted Therapy Causes Regression and Reduced Metastatic Colonization of Pancreatic Neuroendocrine Tumors

Published in 2022 Listed under Basic Science

Download

[B9] Chen - Deletion of Notch1 Signaling in Pancreatic Neuroendocrine Tumors Reduces Metastatic Properties

Published in 2022 Listed under Basic Science

Download

[C10] Pelle - ACTH-secreting Pancreatic Neuroendocrine Neoplasms: A Case-Series

Published in 2022 Listed under Clinical

Download

[C11] Orenbach - Results from the Phase 1, Randomized, Open-Label, Cross-Over Study to Evaluate Pharmacokinetics of Three Escalating Doses of Oral Octreotide Capsules

Published in 2022 Listed under Clinical

Download

[C12] Roy - Financial Toxicity and Supportive Care in Neuroendocrine Tumor: A Biobank Study

Published in 2022 Listed under Clinical

Download

[C13] Blanford - Serum Serotonin Compared to Plasma 5-HIAA and Chromogranin A as Biomarkers of Response to Hepatic Artery Bland Embolization

Published in 2022 Listed under Clinical

Download

[C14] Lee - Cardiac Neuroendocrine Tumor Metastases on 68Ga- DOTATATE PET/CT

Published in 2022

Download

[C15] Delpassand - Effectiveness and Safety of Re-Treatment with 177Lu- DOTATATE in Patients With Progressive NETs in the US: a Retrospective Real-World Study

Published in 2022 Listed under Clinical

Download

[C16] Ensign - Clinical Utility of Somatostatin Receptor Positron Emission Tomography Imaging Biomarkers for Characterization of Meningioma Among Incidental Central Nervous System Lesions

Published in 2022

Download

[C17] Soulen - Integration of Radioembolization with CapTem for Liver-Dominant G2 NETs: Long-Term Outcomes

Published in 2022

Download

[C18] Soulen - Radiosensitization for TARE: Does Duration of Chemotherapy Affect PFS?

Published in 2022 Listed under Clinical

Download

[C19] Cordero - Hernandez - Transformation of G1-G2 Neuroendocrine Tumors (NETs) to Neuroendocrine Carcinomas (NECs) Following Peptide Receptor Radionuclide Therapy (PRRT): A Case Series

Published in 2022

Download

[C1] Singh - Progression-Free Survival in Patients with Bronchopulmonary Neuroendocrine Tumors Treated with Lanreotide or Placebo: Adjustment for Crossover Effects in Placebo Arm

Published in 2022 Listed under Clinical

Download

[C20] Jimenez - Quality of Life Assessments for Advanced Pheochromocytoma and Paraganglioma Patients that Received High-Specific-Activity I-131 MIBG: Results from a Pivotal Phase 2 Clinical Trial

Published in 2022 Listed under Clinical

Download

[C21] Coston - Characterizing Bone Metastases in Patients with Well-Differentiated Neuroendocrine Neoplasms Utilizing Ga68-DOTATATE PET

Published in 2022 Listed under Clinical

Download

[C22] Prela - The Role of 68Ga-DOTATATE PET/CT in the Management of Gastrointestinal and Pancreatic Neuroendocrine Tumors

Published in 2022 Listed under Clinical

Download

[C23] Al-Toubah - Somatostatin Receptor Expression in Lung Neuroendocrine Tumors: An Analysis of Dotatate PET Scans

Published in 2022 Listed under Clinical

Download

[C24] Mittra - MIBG and DOTATATE Therapy for Pheochromocytoma and Paraganglioma: A Single Institution Experience

Published in 2022 Listed under Clinical

Download

[C25] Heying - Evaluation of 68Ga-DOTATATE PET After Two Cycles of Peptide Receptor Radionuclide Therapy (PRRT) in Neuroendocrine Tumors (NET)

Published in 2022 Listed under Clinical

Download

[C26] Mallak - Pre-therapy Functional Imaging with MIBG and DOTATATE to Guide Radiopharmaceutical Therapy for Pheochromocytoma and Paraganglioma: A Single Institution Experience

Published in 2022 Listed under Clinical

Download

[C27] Jha - Performance of 68Ga-DOTATATE PET/CT, 18F-FDG PET/CT, CT, and MRI Spine in the Detection of Spinal Bone Metastases in Metastatic Pheochromocytoma/Paraganglioma

Published in 2022 Listed under Clinical

Download

[C28] Jha - Diagnostic Performance of PET or PET/CT Utilizing 18F-DOPA, 68Ga-DOTATATE, 18F-FDG, 18F-FDA, and CT and MRI in the Detection of MEN2A-relatedpheochromocytoma

Published in 2022 Listed under Clinical

Download

[C29] Jha - Diagnostic Performance of PET or PET/CT Utilizing 18F-DOPA, 68Ga-DOTATATE, 18F-FDG, 18F-FDA, and CT and MRI the Detection of VHL-related Pheochromocytoma

Published in 2022 Listed under Clinical

Download

[C2] Hunter - Pembrolizumab for the Treatment of Recurrent High Grade Neuroendocrine Neoplasms

Published in 2022 Listed under Clinical

Download

[C30] Meloche-Dumas - Liver-Directed Therapy of Neuroendocrine Liver Metastases

Published in 2022 Listed under Clinical

Download

[C31] Patel - Goblet Cell Adenocarcinoma (GCA) of the Appendix: Interrogating Proteomics to Identify Potential Actionable Targets

Published in 2022 Listed under Clinical

Download

[C32] Ziogas - Surgical Management of G3 Gastroenteropancreatic Neuroendocrine Neoplasms: A Systematic Review and Meta-Analysis

Published in 2022 Listed under Clinical

Download

[C33] Taherian -High-Grade Pancreatic Neuroendocrine Neoplasms: Interobserver Diagnostic Accuracy and Relationship with Clinicopathological and Molecular Characteristics

Published in 2022

Download

[C34] Byun - Grade Creep and the Importance of Tissue Sampling: Changes in Ki-67 and Grade in Serial Neuroendocrine Tumor Samples

Published in 2022

Download

[C35] Limbach - Liver Directed Therapy is Associated with Improved Survival in Metastatic Gastroenteropancreatic Neuroendocrine Neoplasms with Concurrent Bone Metastasis

Published in 2022 Listed under Clinical

Download

[C37] Borbon - Is There a Role for Surgical Resection of Grade 3 Neuroendocrine Neoplasms?

Published in 2022 Listed under Clinical

Download

[C38] Concors - Increased Incidence, Prevalence, and Surgical Management of Enteropancreatic Neuroendocrine Tumors Is Associated with Improvements in Survival - A Contemporary Analysis

Published in 2022 Listed under Clinical

Download

[C39] McElroy - Have We Accounted for Asians? A Critical Analysis of Racial Cancer Disparity Amongst Asian Pancreatic Neuroendocrine Tumor Patients

Published in 2022 Listed under Clinical

Download

[C3] Clarke - Real World Analysis of Long-Acting Somatostatin Analog (LA-SSA) Treatment and Dose Escalation Among Patients with Neuroendocrine Tumors (NET)

Published in 2022

Download

[C40] Joseph - TP53 Mutation Portends a Worse Overall Survival in Patients with Advanced Grade 3 Well-Differentiated Neuroendocrine Tumors

Published in 2022 Listed under Clinical

Download

[C41] Chauhan - SSTR-2 Expression in Solid Tumors: An Immunohistochemistry Analysis

Published in 2022 Listed under Clinical

Download

[C42] Pai - Small Intestinal NET Recurrence – When Why and How?

Published in 2022 Listed under Clinical

Download

[C43] Lui - Post-Operative Biochemical Surveillance Thresholds Can be Used to Monitor for Sympathetic Pheochromocytoma/Paraganglioma Recurrence and Metastasis

Published in 2022 Listed under Clinical

Download

[C4] McLaughlin - Cisplatin vs Carboplatin in Extrapulmonary Poorly Differentiated Neuroendocrine Carcinomas (PD NEC)

Published in 2022 Listed under Clinical

Download

[C5] Ghosh - c-MET Expression in MEN1-associated Neuroendocrine Tumors

Published in 2022 Listed under Clinical

Download

[C6] Eads - An Open-Label, Phase 1b/2 study of Surufatinib in Combination with Tislelizumab in Patients with Advanced Neuroendocrine Tumors

Published in 2022 Listed under Clinical

Download

[C7] Al-Toubah - Risk of Myelodysplastic Syndrome/Acute Leukemia with Sequential Capecitabine/Temozolomide and 177Lu-Dotatate

Published in 2022 Listed under Clinical

Download

[C8] Al-Toubah - Phase II Study of Pembrolizumab and Lenvatinib in Advanced Well-Differentiated Neuroendocrine Tumors

Published in 2022 Listed under Clinical

Download

[C9] Lee - Correlation of MEN1 and DAXX Mutational Status with Response to Capecitabine and Temozolomide (CAPTEM) in Pancreatic Neuroendocrine Tumors

Published in 2022 Listed under Clinical

Download

[O10] Sonbol - Germline Cancer Testing in Unselected Patients with Neuroendocrine Neoplasms: A Multi-center Prospective Study

Published in 2022 Listed under OT

Download

[O11] Rose-Krasnor - Pheo Para Alliance Patient Centered Research on Challenges for Those with Pheochromocytoma and Paraganglioma

Published in 2022 Listed under OT

Download

[O12] Trikalinos - An Appraisal of Findings from a Neuroendocrine Neoplasm (NEN) Tumor Board (TB): Is There Added Value or Is It Redundant?

Published in 2022 Listed under OT

Download

[O1] Das - Efficacy and Toxicity of Anti-Vascular Endothelial Growth Factor (VEGF) Receptor Tyrosine Kinase Inhibitors (TKIs) in Neuroendocrine Tumors (NETs) – A Systematic Review and Meta-Analysis

Published in 2022 Listed under OT

Download

[O2] Duncan - The Association Between Patient-Reported Symptom Burden and Urgent Healthcare Use in Patients Diagnosed with Neuroendocrine Tumors

Published in 2022 Listed under OT

Download

[O3] Moon - Germline Pathogenic Variants in Patients with High- Grade (G3) Metastatic Gastroenteropancreatic (GEP) Neuroendocrine Neoplasms (NENs)

Published in 2022 Listed under OT

Download

[O4] Alaklabi - Immune Cell Molecular Pharmacodynamics of Lanreotide in Relation to Treatment Response

Published in 2022 Listed under OT

Download

[O5] Benard - Implementation of a Patient Advisor Program for Neuroendocrine Tumor Patients: Acceptability, Benefits and Potential Challenges

Published in 2022 Listed under OT

Download

[O6] Ramirez - Frequency of Pulmonary Carcinoid Tumor Research Presented at Major International Neuroendocrine and Lung Cancer Scientific Meetings

Published in 2022 Listed under OT

Download

[O7] Hunter - Circulating Tumor DNA Detection Using a Personalized, Tumor-Informed Assay in Metastatic Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumor Patients

Published in 2022 Listed under OT

Download

[O8] Moon - Variants of Uncertain Significance (VUS) are More Common in Non-Caucasian Patients with Neuroendocrine Neoplasms (NENs)

Published in 2022 Listed under OT

Download

[O9] Lou - Leveraging Transcriptomics to Grade Pancreatic Neuroendocrine Neoplasms(NENs) and Assess Molecular Alterations Associated with Somatostatin Receptor(SSTR) Subtype Expression

Published in 2022 Listed under OT

Download

[P10] Ituarte - Environmental Pollution and GEP-NENS – Is There an Association?

Published in 2022 Listed under P

Download

[P1] Diamantopoulous - Cervical Neuroendocrine Carcinomas: A Population- Based Analysis of Clinicopathologic Characteristics and Survival Outcomes in Comparison with Conventional Cervical Malignancies

Published in 2022 Listed under P

Download

[P2] Chu - Factors Impacting Survival Outcomes of Islet Cell Carcinoma

Published in 2022 Listed under P

Download

[P3] Hu - Socioeconomic Factors, Treatment Modality, and Survival in Islet Cell Carcinoma: A National Cancer Database Analysis

Published in 2022

Download

[P5] Laderian - Comparison of Demographics and Overall Survival (OS) Among Patients with Young-Onset(YO) and Late- Onset(LO) GI Neuroendocrine Tumors/Carcinomas (NETs/NECs) in the United States

Published in 2022 Listed under P

Download

[P6] Ackbarali - Evaluating the Impact of Education on Clinician Integration of Guidelines, Real-World Data, and Patient Perspectives on Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)

Published in 2022 Listed under P

Download

[P7] Mulvey - Feasibility of e-NET: A Web-Based Health Platform to Investigate Quality of Life in Patients with Neuroendocrine Tumors

Published in 2022 Listed under P

Download

[P8] Hernandez - Multivisceral Surgical Resection of Locally Advanced Pancreatic Neuroendocrine Tumor is Associated with a Survival Benefit

Published in 2022 Listed under P

Download

[P9] Bogaards - Lifestyle and Neuro-endocrine Tumor (NET) Development Within the European Prospective Investigation into Cancer and Nutrition (EPIC) Cohort

Published in 2022 Listed under P

Download

[T10] Mohamed - Pilot Study of TQ Formula in Combination with Nivolumab and Ipilimumab in Metastatic Gastroenteropancreatic Neuroendocrine Carcinomas (GEP-NECAs)

Published in 2022 Listed under T

Download

[T1] Stockton - Phase Ia/Ib Study of BAY1895344 Plus Topoisomerase I Inhibitors with a Focus on Poorly Differentiated Neuroendocrine Carcinomas and Pancreatic Adenocarcinoma

Published in 2022 Listed under T

Download

[T2] Halfdanarson - COMPOSE: Pivotal Phase III Trial for Well- Differentiated Aggressive Grade 2/3 Gastroenteropancreatic Neuroendocrine Tumors Comparing 177Lu-edotreotide with Best Standard of Care

Published in 2022 Listed under T

Download

[T3] Chauhan - Phase 2 Study to Evaluate the Safety, Pharmacokinetics, and Dose Response of Paltusotine Carcinoid Syndrome

Published in 2022 Listed under T

Download

[T4] McGarrah - Phase 1-2 Trial of Vesicular Stomatitis Virus Expressing Human Interferon-β and NIS (VSVIFNβ- NIS), with Pembrolizumab, in Patients with Neuroendocrine Carcinoma

Published in 2022 Listed under T

Download

[T5] Jimenez - A Phase 2 Open-Label Study of Belzutifan (a HIF-2α Inhibitor) Monotherapy in Patients with Advanced/Metastatic Pheochromocytoma/ Paraganglioma or Pancreatic Neuroendocrine Tumors

Published in 2022 Listed under T

Download

[T6] Hope - ACTION-1: A Randomized Phase Ib/3 trial of RYZ101 Compared with SoC in SSTR2+ Well-Differentiated GEP-NET with Progression Following Lu-177 SSA

Published in 2022 Listed under T

Download

[T7] Singh - Methodology of the SORENTO Clinical Trial: Assessing Efficacy and Safety of High Exposure Octreotide Subcutaneous Depot in Patients with GEP-NET

Published in 2022 Listed under T

Download

[T8] Chauhan - Phase II Trial Evaluating [177Lu]Lu-DOTA-TATE in Adolescents with Somatostatin Receptor (SSTR)- positive Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs), Pheochromocytomas and Paragangliomas (PPGLs)

Published in 2022 Listed under T

Download

[T9] Puranik - PReCedeNT Trial: Phase III Randomised Controlled Trial of PRRT with Lutetium – 177 DOTATATE Plus Chemotherapy Versus PRRT Alone in FDG-avid, Well-Differentiated Gastro-Entero-Pancreatic Neuroendocrine Tumors

Published in 2022 Listed under T

Download

NANETS

136 Everett Rd | Albany, NY 12205
(650) 7NANETS or (518) 465-4549 | staff@nanets.net

Member Login

Twitter Facebook LinkedIn
  • Privacy Policy
  • |
  • Site Map

Copyright ©2023 ADG. All Rights Reserved | Web Design & Development by ADG Creative, a division of ADG.
ADG is a certified Women Owned Business.